Janux Q4 2022 Earnings Report
Key Takeaways
Janux Therapeutics reported financial results for the fourth quarter and full year ended December 31, 2022. The company's lead program PSMA-TRACTr (JANX007) continues to enroll in first-in-human Phase 1 clinical trial in prostate cancer patients and Janux received FDA clearance for Investigational New Drug (IND) application for EGFR-TRACTr (JANX008).
Lead program PSMA-TRACTr (JANX007) continues to enroll in first-in-human Phase 1 clinical trial in prostate cancer patients.
Janux received U.S. Food and Drug Administration (FDA) clearance for an IND application for EGFR-TRACTr (JANX008).
PD-L1xCD28 TRACIr (JANX009) on-track for an IND submission in 2023.
TROP2-TRACTr evaluations to support development candidate selection are ongoing.
Janux
Janux
Forward Guidance
Janux anticipates providing an interim clinical update from the PSMA-TRACTr (JANX007) trial in the second half of 2023. In addition, Janux expects to select a development candidate for its TROP2-TRACTr in 2023.